Related Experiment Videos
Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired
Ting-Yen Chiang1, Ling-Yuh Shyu, Thomas-Chang Yao Tsao
1School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Background:
The purpose here was to detect the association among plasma matrix metalloproteinase-9 (MMP-9) concentration, single nucleotide polymorphisms (SNPs) of MMP-9 gene and community-acquired pneumonia (CAP).
Methods:
The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively used to measure the plasma MMP-9 level and its gene polymorphisms.
Results:
The level of plasma of MMP-9 was elevated in patients with CAP as compared to that of normal controls and decreased significantly after treatment. Plasma MMP-9 concentration was significantly correlated with white blood cell (WBC) and neutrophil counts in patients with CAP. No significant difference was found in the genotypes distribution of MMP-9 SNPs, rs3918242, rs17576 or rs2274756, between patients with CAP and normal controls. Plasma MMP-9 concentration was not associated with MMP-9 polymorphism. When the cut-off level of the plasma MMP-9 concentration was set to be 105.02 ng/mL, the odds ratio of plasma MMP-9 for CAP risk was 9.86 (95% confident interval: 4.27-22.75). Plasma MMP-9 level may act as a prediction marker for CAP.
Conclusions:
Elevated plasma MMP-9 could be a biological marker for the diagnosis and be a new strategy for target therapy of community-acquired pneumonia.
Insights
Elevated plasma matrix metalloproteinase-9 (MMP-9) levels are associated with community-acquired pneumonia (CAP) and may serve as a diagnostic marker. MMP-9 gene polymorphisms were not linked to CAP risk in this study.
Area of Science:
- Biochemistry
- Genetics
- Pulmonology
Background:
- Community-acquired pneumonia (CAP) poses a significant health burden.
- Matrix metalloproteinase-9 (MMP-9) is implicated in inflammatory processes.
- Understanding MMP-9's role in CAP is crucial for diagnosis and treatment.
Purpose of the Study:
- To investigate the association between plasma MMP-9 concentration, MMP-9 gene single nucleotide polymorphisms (SNPs), and CAP.
- To evaluate plasma MMP-9 as a potential diagnostic biomarker for CAP.
Main Methods:
- Plasma MMP-9 levels were measured using enzyme-linked immunosorbent assay (ELISA).
- MMP-9 gene polymorphisms (rs3918242, rs17576, rs2274756) were analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Main Results:
- Plasma MMP-9 levels were significantly higher in CAP patients than in controls and decreased post-treatment.
- Plasma MMP-9 concentration correlated with white blood cell and neutrophil counts.
- No significant association was found between MMP-9 SNPs and CAP. A plasma MMP-9 cut-off of 105.02 ng/mL indicated a 9.86-fold increased risk for CAP.
Conclusions:
- Elevated plasma MMP-9 is a potential diagnostic biomarker for CAP.
- Plasma MMP-9 levels may guide targeted therapy strategies for CAP.
- MMP-9 gene polymorphisms are not directly associated with CAP risk in the studied population.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Atypical Pneumonia
Clinical Significance of Antibiotic Resistance
Pneumonia I: Introduction
Mechanism of Antibiotic Resistance in MRSA
Pneumonia III: Complications and Assessment